Latin America conference-aay 1 session 1: Introduction to biotherapeutic medicines & regulation

Latin America Conference Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 — 20 November 2013

Latin America conference-day 1 session 2: Regulatory pathways for drug approval of biotherapeutic & biosimilar medicines

Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 — 20 November 2013

Latin America conference-day 1 session 3: Developmental challenges & scientific considerations

Latin America Conference Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 — 20 November 2013

Latin America conference-day 2 session 1: Perspective on biotherapeutic & biosimilar medicines regulation

Latin America Conference Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 — 20 November 2013

Latin America conference-day 2 session 2: Key aspects of pharmacovigilance & naming

Latin America Conference Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 — 20 November 2013

Latin America conference-day 2 after lunch break

Latin America Conference Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 — 20 November 2013

Latin America conference-day 2 session 3: Points of view, interchangeability & substitution

Latin America Conference Biotherapeutics Medicines — Sharing Experiences and Best Practices Lima, Peru, 19 – 20 November 2013

Latin America conference-day 2 session 4: Panel discussion

Latin America Conference Biotherapeutics Medicines – Sharing Experiences and Best Practices Lima, Peru, 19 – 20 November 2013

NCDs & influenza infographic

IFPMA 2014 interview series ‘The Value of investing in immunization’

Immunization has shown excellent results against infectious diseases such as polio and measles, but continued success requires sustained political and financial commitment. Unfortunately, immunization as a whole remains an unfinished business as too many children are still dying of vaccine preventable diseases. As President and General Manager of Pfizer’s Vaccines and an IFPMA Vaccine CEO...